The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
The National Institute for Health and Care Excellence has published draft guidance that recommends fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer following 2 or more anti-HER2 therapies.
As longer-term follow-up data become available for several agents approved for HER2-positive metastatic breast cancer, investigators are looking closely at the characteristics of patients enrolled in those clinical trials to determine appropriate treatment strategies in the third-line setting and beyond.
Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.
Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.
Experts highlight the risk factors, comorbidities, diagnosis, economic burden, and treatments for brain metastasis in metastatic breast cancer based on data presented at the 2020 San Antonio Breast Cancer Symposium.
Debu Tripathy, MD, discusses some of the unanswered clinical questions that remain for patients with HER2-positive disease and some strategies for personalizing treatment in the neoadjuvant and adjuvant settings.
With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.
The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.
February 12, 2021 - The European Commission has granted marketing authorization to tucatinib for use in combination with trastuzumab and capecitabine in the treatment of adult patients with HER2-positive, locally advanced or metastatic breast cancer who have previously received at least 2 HER2-targeted regimens
January 20, 2021 - The antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-based regimens.